Endogenex™ Appoints Krissy Wright as Chief Financial Officer

January 14, 2025 01:32 PM GMT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Endogenex™ Appoints Krissy Wright as Chief Financial Officer
Image source: Kalkine Media

Bringing finance, operational, and corporate development expertise to an experienced leadership team.

MINNEAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Endogenex, Inc., a clinical-stage medical device company, is proud to announce the addition of Krissy Wright as Chief Financial Officer (CFO). In this role, Wright will lead Endogenex's financial strategy, corporate development initiatives, and operational planning to support the advancement of the company's clinical initiatives.

"We are thrilled to welcome Krissy to the Endogenex leadership team," said Stacey Pugh, CEO of Endogenex. "Her extensive experience in financial strategy, corporate development, and leadership in the MedTech industry will be instrumental as we work to achieve our clinical milestones and deliver transformative solutions to type 2 diabetes management."

Krissy brings experience from Cleerly, an AI-driven heart diagnostics company, where she served as CFO, and from Medtronic, where she held leadership roles including Vice President and General Manager of Brain Modulation and Vice President and Chief Financial Officer for the Neuromodulation Operating Unit. Earlier in her career, she spent 11 years at PricewaterhouseCoopers, specializing in Audit, Assurance, and Transaction Services.

"I am thrilled to be joining Endogenex at such a pivotal moment in its journey," said Wright. "The company's novel approach to addressing type 2 diabetes can potentially transform the lives of millions worldwide. I look forward to leveraging my financial expertise to support the team in advancing this groundbreaking therapy and achieving our mission of delivering meaningful, scalable healthcare solutions."

The ReCET Procedure:
ReCET is a novel, endoscopic, outpatient procedure that targets the underlying cellular abnormalities in the duodenum that contribute to the development and progression of type 2 diabetes.

By applying highly controlled, non-thermal pulsed electric fields, the ReCET Procedure is designed to initiate the body's natural regenerative process to restore proper cellular signaling from the duodenum and improve glycemic control.

The ReCET Procedure is currently being evaluated in global pre-commercialization trials assessing its safety and efficacy in adults with type 2 diabetes who are inadequately controlled despite the use of insulin and non-insulin medications. The ReCET Procedure has received Breakthrough Device Designation from the FDA for the treatment of type 2 diabetes in adult patients inadequately controlled by glucose-lowering medications.

About Endogenex:
Endogenex is a privately held, clinical-stage company headquartered in Minneapolis, MN. Endogenex was founded in partnership with Mayo Clinic to develop therapies to improve outcomes for people living with type 2 diabetes. Endogenex focuses on the principle that effective treatment for type 2 diabetes can extend beyond pharmaceutical options, correct metabolic function, and help people regain control of their blood glucose levels.

For more information, please visit our website at www.endogenex.com.

Media Inquiries:
Krissy Wright
[email protected]
+1 651 329 5413

Logo - https://mma.prnasia.com/media2/2446687/2312_1673_DY23_ENDOGENEX_HORIZONTAL_LOGO_POSITIVE_CMYK_Logo_Logo.jpg?p=medium600


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AI on the Rise: A Look at Top AI Companies and Their Stocks

Recent Articles

Investing Tips

Previous Next